uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
SYMPTOMS, RISK CLASSIFICATION, AND SPLEEN SIZE IN JAK2 INHIBITOR-NAIVE MYELOFIBROSIS: IMPLICATIONS FOR JAK2 INHIBITOR TREATMENT
OHSU, Hematol & Oncol, Portland, OR USA.;Mayo Clin, Hematol & Oncol, Scottsdale, AZ USA..
Mayo Clin, Phoenix, AZ USA..
Mayo Clin, Phoenix, AZ USA.;Mayo Clin, Internal Med, Scottsdale, AZ USA..
Mayo Clin, Phoenix, AZ USA..
Show others and affiliations
2016 (English)In: Haematologica, ISSN 0390-6078, E-ISSN 1592-8721, Vol. 101, 557-558 p.Article in journal, Meeting abstract (Other academic) Published
Resource type
Text
Place, publisher, year, edition, pages
2016. Vol. 101, 557-558 p.
National Category
Hematology
Identifiers
URN: urn:nbn:se:uu:diva-301459ISI: 000379484602135OAI: oai:DiVA.org:uu-301459DiVA: diva2:954807
Conference
21st Congress of the European-Hematology-Association, JUN 09-12, 2016, Copenhagen, DENMARK
Available from: 2016-08-23 Created: 2016-08-23 Last updated: 2016-08-23Bibliographically approved

Open Access in DiVA

No full text

Search in DiVA

By author/editor
Birgegård, Gunnar
By organisation
Haematology
In the same journal
Haematologica
Hematology

Search outside of DiVA

GoogleGoogle Scholar

Total: 177 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf